Výsledky vyhledávání

Abstract P6-14-18: Updated Survival Analysis of a Phase III Study (EMBRACE) of Eribulin Mesylate Versus Treatment of Physician's Choice in Subjects with Locally Recurrent or Metastatic Breast Cancer Previously Treated with an Anthracycline and a Taxane

Autor: Jantien Wanders, J. Cortes, S. Seegobin, Chris Twelves, X Durando, D. Loesch, Joanne L. Blum, Linda T. Vahdat, K. Petrakova, C Akerele

Publikováno v: Cancer Research. 70:P6-14

Background: Eribulin mesylate (E7389) is a non-taxane microtubule dynamics inhibitor with a novel mode of action. EMBRACE was the first trial to compare overall survival (OS) of this new chemotherapeutic agent to real-life treatment choices (treatmen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ecc2a5275e282efc081cce35ce2e4c5c
https://doi.org/10.1158/0008-5472.sabcs10-p6-14-18

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Protein profiling of ovarian cancers by immunohistochemistry to identify potential target pathways

Autor: R. Bender, Ivor Benjamin, Bradley J. Monk, Dana M. Chase, D. Loesch, A. Alacron, John H. Farley, Heather J. Dalton

Publikováno v: Gynecologic Oncology Research and Practice

Background To determine the protein expression profile (PEP) of primary and recurrent ovarian cancer patients in order to predict therapeutic targets for chemotherapy. Methods Tissue samples were submitted for PEP in two formats, including formalin-f

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59a8dd2eabdeddabdd3d76f476d79791
https://doi.org/10.1186/2053-6844-1-4

Zobrazit plný text záznamu

Tandem autotransplantation for the treatment of metastatic breast cancer

Autor: George W. Sledge, Lawrence H. Einhorn, D Loesch, R Sridhara, Robert Hromas, E R Broun, P H Kneebone, Mark Hanna, K Cornetta

Publikováno v: Journal of Clinical Oncology. 13:2050-2055

PURPOSE To investigate the tolerability and impact on progression-free and overall survival of two consecutive cycles of high-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) in patients with previously untreated metastatic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2801a68cd97b7f15cde396290d698ee4
https://doi.org/10.1200/jco.1995.13.8.2050

Zobrazit plný text záznamu

Trends in Gerontological Counselor Preparation

Autor: Thomas J. Sweeney, Larry D. Loesch, Jane E. Myers

Publikováno v: Counselor Education and Supervision. 30:194-204

This study identifies current trends in preparation of counselors to work with older persons, including specialty course work in gerontological counseling and the extent to which gerontological counseling content and issues are incorporated into exis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::0325ccdc5ccf4c9541bf4bbf80be559e
https://doi.org/10.1002/j.1556-6978.1991.tb01200.x

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

A phase II trial of high dose epirubicin in patients with advanced breast carcinoma

Autor: D K, Miller, N, Munshi, D, Loesch, L E, Einhorn, G W, Sledge

Publikováno v: Cancer. 88(2)

Anthracyclines are among the most active drugs in the treatment of breast carcinoma and exhibit a steep dose-response curve in vitro. This trial was performed to determine the efficacy and toxicity of epirubicin in the treatment of patients with adva

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::43f0c26d561599e80ff7c02b6be17da0
https://pubmed.ncbi.nlm.nih.gov/10640971

Zobrazit plný text záznamu

A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy

Autor: M S, Gordon, W J, McCaskill-Stevens, L A, Battiato, J, Loewy, D, Loesch, E, Breeden, R, Hoffman, K J, Beach, B, Kuca, J, Kaye, G W, Sledge

Publikováno v: Blood. 87(9)

We performed a phase I trial of recombinant human interleukin-11 (rhIL-11) in women with breast cancer. Cohorts of three to five women were accrued to five dosage levels of rhIL-11 (10, 25, 50, 75, and 100 micrograms/kg/d). rhIL-11 alone was administ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0b7dbb3179b193393dfaae7cb0e74b28
https://pubmed.ncbi.nlm.nih.gov/8611685

Zobrazit plný text záznamu

A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane

Autor: Jantien Wanders, Joanne L. Blum, Linda T. Vahdat, Chris Twelves, C Akerele, D. Loesch, Philippe Chollet, J. Cortes, S. Seegobin, K. Petrakova

Publikováno v: Journal of Clinical Oncology. 28:CRA1004-CRA1004

CRA1004^ Background: Eribulin mesylate (E7389; E) is a nontaxane microtubule dynamics inhibitor with a novel mode of action. This study is the first to compare overall survival (OS) with this new chemotherapeutic (CT) agent to real-life choices in he

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7926cfeae6f79709db1b15eb2975c9ab
https://doi.org/10.1200/jco.2010.28.18_suppl.cra1004

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání